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Abstract 
 
Since breast cancer is the most common cancer among women worldwide 
and the relative 10-years overall survival is 80% there is an increasing 
number of women living with a history of breast cancer treatment. This 
results in a great number of women in the society having received breast 
cancer radiotherapy. The purpose of this study was to identify and quantify 
self-reported long-term symptoms/side-effects caused by irradiation and 
correlate these to patient and treatment related risk factors. Furthermore, we 
wanted to investigate how the dose-volume distribution of ionizing radiation 
delivered to a certain anatomical volume contributed to the occurrence of 
certain symptoms, i.e. a dose-volume response analysis. 
We interviewed women that were treated with breast cancer surgery and 
postoperative radiotherapy up to 20 years earlier; based on these interviews 
we made a questionnaire. The questionnaire was sent to two different cohorts 
of women having had breast cancer treatment three to 17 years earlier. Cohort 
1: 422 women who were randomised between 1991 and 1997 to receive 
adjuvant tangential breast irradiation or not after breast conserving surgery 
with axillary dissection. Cohort 2: 1091 women who had adjuvant breast 
cancer radiotherapy based on a 3D-dose plan between 1999 and 2004 at 
Sahlgrenska University Hospital, Gothenburg.  
Paper I: Based on cohort 1 we found that 8.8% of the women having 
undergone radiotherapy and surgery reported weekly breast pain versus 0.6% 
of the women with surgery alone (RR 15.1 95% CI 2.03-112). Significantly 
increased occurrence after radiotherapy was also observed for disturbances of 
skin sensation. Daily life and analgesic use did not differ between the groups. 
Paper II: Our next step was to identify risk factors that contributed to breast 
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pain after breast cancer radiotherapy (cohort 1 and 2). Higher age at treatment 
(RR 0.96; 95% CI 0.94-0.98, annual decrease) and longer time since 
treatment (RR 0.93; 95% CI 0.88-0.98, annual decrease) were related to a 
lower occurrence of breast pain. For example among women up to 39 years 
of age at treatment, 23.1% had breast pain, compared with 8.7% among 
women older than 60 years (RR 2.66; 95% CI 1.33-5.36). In paper III and IV 
we reported long-term symptoms after radiotherapy including the regional 
lymph nodes, i.e. irradiation of the plexus brachialis, or not (cohort 2). We 
found that paraesthesia in the hand was reported by 20% after regional 
radiotherapy compared to 13% without regional radiotherapy (RR 1.47; 95% 
CI 1.02-2.11). RR adjusted for oedema in the hand (RR 1.28; 95% CI 0.93-
1.76). Among the women who received irradiation >40 Gy to a volume of 
>13.5 cm3 of the brachial plexus 25% reported paraesthesia, RR 1.83 (95% 
CI 1.13-2.95). The risk was still significant after adjustment for oedema (RR 
1.64; 95% CI 1.12-2.41). 
Conclusions: Radiotherapy after breast-conserving surgery among women 
treated for breast cancer increases the occurrence of breast pain, especially 
among younger women. Furthermore, regional radiotherapy increases the 
occurrence of paraesthesia in the hand and our results indicate that there 
seems to be a correlation between larger irradiated brachial nerve volumes 
and an increased risk of reporting paraesthesia. 
 
Keywords: Radiotherapy, breast cancer, long-term symptoms, breast pain, 
supra clavicular,  plexus brachialis. 
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Sammanfattning på svenska 
Bröstcancer är den vanligaste formen av cancer bland kvinnor, och i Sverige 
kommer var tionde kvinna att få bröstcancer under sin livstid. 
Långtidsresultaten för hela bröstcancergruppen är goda med en relativ tio års 
överlevnad kring 80 procent. Detta innebär att vi har en växande grupp av 
”canceröverlevare” vilka kommer att leva under många år med eventuella 
behandlingsrelaterade biverkningar från exempelvis kirurgi, kemoterapi och 
strålbehandling. Vi vet att tillägget av strålbehandling efter bröstcancerkirurgi 
minskar återfallsrisken vilket i sin tur leder till en förlängd överlevnad. 
Metaanalyser visar att för vart fjärde lokalrecidiv som undviks med 
strålbehandling så räddas en kvinna från att dö i bröstcancer.  
Detta arbete syftar till att identifiera och kvantifiera självrapporterade 
bestående strålrelaterade symtom av en modern strålbehandlingsteknik samt 
att söka efter patient- och behandlingsrelaterade riskfaktorer. Vidare att 
studera hur förekomst av symtom på lång sikt varierar med dos inom 
specifika anatomiska områden.  
Vi hade som mål att skapa ett frågeformulär (så heltäckande som möjligt) 
som byggde på patientens egna upplevelser ur vardagen flera år efter avslutad 
behandling. Vi utvecklade ett formulär som var baserat på semistrukturerade 
djupintervjuer med kvinnor som behandlats för bröstcancer 3 till 20 år 
tidigare. Nya intervjuer genomfördes fram tills inga ytterligare symtom togs 
upp av de intervjuade kvinnorna (symtommättnad). Totalt intervjuades 22 
kvinnor vilka alla hade behandlats med olika former av kirurgi och 
strålbehandling. Utifrån deras angivna symtom utformades ett omfattande 
frågeformulär (80 sidor). Frågorna i formuläret ansiktsvaliderades sedan med 
kvinnor som genomgått bröstcancerbehandling för att vi skulle försäkra oss 
om att frågorna förstods på det sätt vi tänkt oss och därmed passa till den 
grupp av kvinnor som skulle ingå i studien. En pilotstudie genomfördes 
därefter för att bedöma vilken svarsfrekvens som kvinnor i denna grupp har 
för formuläret och ifall någon specifik fråga skulle bli obesvarad. Vi fortsatte 
med huvudstudien när 30 av 32 formulär besvarats.  
Under 2007och 2008 tog vi kontakt med och skickade formulär till två olika 
grupper av återfallsfria bröstcancerbehandlade kvinnor. Kravet på 
återfallsfrihet var för att vi inte skulle blanda samman symtom av sjukdom 
med symtom relaterade till behandling.  
Patientgrupp 1: För att kunna urskilja strålorsakade symtom från 
kirurgiorsakade symtom skickade vi under 2007 enkäten till kvinnor (antal 
422 st) som varit med i en svensk randomiserad studie, SweBCG91-RT, 
mellan åren 1991 och 1997, dvs. 10 till 17 år tidigare.  Kvinnorna hade 
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genomgått sektorresektion och axillutrymning p.g.a. lokaliserad bröstcancer 
mindre än 5 cm och utan lymfkörtelspridning. De randomiserades till 
tangentiell strålbehandling av bröstet eller ingen ytterligare behandling.  
Patientgrupp 2: Under 1999 blev det standard med 3D-dosplanering på 
Jubileumskliniken, Sahlgrenska Universitetssjukhuset i Göteborg för alla 
kvinnor med bröstcancer. Under 2008 kontaktade vi kvinnor som fortlöpande 
blivit strålbehandlade på Jubileumskliniken, Sahlgrenska 
Universitetssjukhuset under perioden 1999 tom 2004, dvs. 3 till 9 år tidigare 
(antal 1091 st). Syftet med denna grupp var att få beskrivit symtomen från 
kvinnor som fått en mer varierad, modern och avancerad strålbehandling 
samt där även dessa kvinnors 3D-dosplaner fanns tillgängliga för att mer 
specifikt studera dosens betydelse inom olika volymer för uppkomsten av 
symtom. 
Resultat:  
I artikel 1 jämför vi symtom efter bröstbevarande kirurgi och strålbehandling 
med symtom efter bröstbevarande kirurgi enbart. Vi fann att kvinnor som fått 
strålbehandling rapporterade ömhet i bröstet oftare, 8.8%, i jämförelse med 
de kvinnor som inte fått strålbehandling, 0.6%. Vidare fann vi en ökad 
förekomst av känselstörningar i huden efter strålbehandling. Det fanns dock 
ingen skillnad gällande konsumtionen av smärtstillande tabletter eller 
välbefinnande mellan grupperna. Syftet med artikel 2 var att finna 
riskfaktorer bakom bröstömhet 3 – 17 år efter bröstbevarande kirurgi och 
strålbehandling av bröstet. Åldern visade sig vara den viktigaste faktorn. 
Förekomsten av bröstömhet var 9 % i gruppen över 60 år, 12 % i gruppen 50 
– 59 år, 21 % i gruppen 40 – 49 år och 23 % bland kvinnorna yngre än 40 år. 
Kort tid sedan behandling var också relaterat till en högre förekomst av 
bröstömhet, förekomsten av bröstömhet var 16 % i gruppen som hade 
behandlats för 3 – 5 år sedan, 13 % efter 6 – 9 år och 9 % efter 10 – 17 år. I 
artikel 3 jämför vi symtom i hand/arm med eller utan regional lymfkörtel 
strålbehandling. Denna strålbehandling ger också dos till plexus brachialis 
(armens känsel- och motoriknerv). Efter axillkirurgi och regional 
strålbehandling rapporterade 20 % stickningar i handen i jämförelse med 13 
% utan strålbehandling. Förekomsten av svullnad i handen var 22 % efter 
strålbehandling jämfört med 15 % utan strålbehandling. Om man justerar 
stickningarna för svullnad försvinner den säkerställda skillnaden, d.v.s. det 
kan också vara svullnaden som indirekt orsakar stickningarna i tillägg till en 
direkt strålpåverkan av nerven. I artikel 4 fann vi att bland de kvinnorna som 
fått en stråldos av minst 40.0 Gy till en stor volym (>13.5 cm3) av plexus 
brachialis rapporterade 25 % stickningar i jämförelse med 13 % utan 
strålbehandling. Även efter justering för svullnad kvarstår stor bestrålad 
volym som en riskfaktor för stickningar i handen vilket tyder på en direkt 
strålpåverkan av nerven. 
Slutsatser:  
Resultaten av våra studier tyder på att: Postoperativ strålbehandling av 
bröstet, i tillägg till bröstbevarande kirurgi, leder till en ökad förekomst av 
ömhet i bröstet. Störst risk för bröstömhet har de yngre kvinnorna. 
Strålbehandling av de regionala lymfkörtlarna leder till en ökad förekomst av 
stickningar i handen. Dessutom att det finns en relation mellan dos till plexus 
brachialis och stickningar i handen. 
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Abbreviations 
2D Two-dimensional 
3D Three-dimensional 
APBI Accelerated Partial Breast Irradiation 
ALND Axillary Lymph Node Dissection 
BCS Breast-Conserving Surgery 
BMI  Body Mass Index, kg/m2 
BPN Brachial Plexus Neuropahy 
CMF Cyclophosphamide, Methotrexate, and 5-fluorouracil 
CI Confidence Interval 
CT Computed Tomography 
DVH Dose Volume Histogram 
EBCTCG Early Breast Cancer Trialists' Collaborative Group 
ER Estrogen Receptor 
EQD2Gy Equalized total dose in 2 Gy/fraction 
FAC/FEC 5-fluorouracil, anthracyclin (epirubicin/doxorubicin), and 
 cyclophosphamide 
Gy Gray, the SI unit for absorbed radiation dose (1 Gy = 1            
 Joule/kg) 
IMRT Intensity-Modulated Radiation Therapy   
ITT Intention To Treat 
LENT Late Effects of Normal Tissue 
LINAC Linear Accelerator 
MV MegaVolts  
PTV Planning Target Volume 
RR Relative Risk 
RT Radiotherapy 
RTOG Radiation Therapy Oncology Group 
SLND Sentinel Lymph Node Dissection 
SOMA  Subjective, Objective, Management, Analytic scale 
START Standardisation of Breast Radiotherapy 
SweBCG91-RT  Swedish Breast Cancer Group 1991 RadioTherapy-trial 
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1 Background 
1.1 Breast Cancer 
1.1.1 Epidemiology 
With 1.6 million new cases each year, breast cancer is the most common 
invasive cancer among women worldwide [1]. In Sweden 7917 new cancers 
were diagnosed in 2010, which constituted 30% of all female cancer [2]. The 
breast cancer incidence for women has increased both worldwide and in 
Sweden. The annual increase in Sweden has been 1.3% during the previous 
20 years; however the yearly increase during the previous 10 years is smaller, 
0.9%. Known risk factors are: age (two thirds of breast cancer cases occur 
after the age of 55), heredity (e.g. BRCA 1-2), low age at menarche (before 
age 11), high age at menopause (after age 54), null parity, high age at first 
childbirth, BMI > 35 (postmenopausal), using hormonal replacement therapy 
(HRT) for many years, and exposure to ionizing radiation, especially at a 
young age [3-5]. Approximately 1500 women die every year in Sweden due 
to breast cancer. The number of deaths due to breast cancer has been more or 
less constant for decades, which implies, among other things, that the 
treatment has become more effective. Furthermore, screening with 
mammography also contributes to the improvement by finding early breast 
cancers. The relative five- and ten-year survivals in Sweden are today 89% 
and 79% respectively compared to 72% and 58% during the 1970s [6]. The 
prevalence of women who have been treated for breast cancer is therefore 
increasing; in 2007 the total prevalence was more than 84 000 women in 
Sweden.  
 
1.1.2 Screening 
Mammography has been used since the 1980s in Sweden and the National 
Board of Health and Welfare (Socialstyrelsen) recommends that women 
between 40 and 74 years old participate. Mammography increases the chance 
to find early cancer and thereby increases the chance for cure. The greatest 
effect is among women between 50 and 69 years old [7]. 
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1.1.3 Treatment 
Treatment of breast cancer is often a combination of local treatment (surgery 
and radiotherapy) to control local disease and systemic treatment against 
micrometastatic disease (endocrine therapy, chemotherapy, targeted drugs). 
Surgery 
The American surgeon W.S. Halsted showed in 1894 that women with breast 
cancer who had a radical mastectomy with removal of the underlying 
pectoralis muscles and axillary lymph nodes en bloc lived longer than women 
without treatment [8]. During this time period breast cancer was believed to 
be a locally spreading disease and the surgery performed was extensive. This 
radical surgery reduced breast cancer mortality, however, giving this 
extensive and maximum tolerated treatment resulted in extensive morbidity. 
In the middle of the 20th century a less extensive form of mastectomy, leaving 
the pectoralis muscles intact, was introduced and the technique of modified 
radical mastectomy was born [9]. Modified radical mastectomy was then 
considered as the standard surgical treatment of breast cancer for decades. 
Ideas that breast cancer could spread systemically instead of only locally and 
that the surgery should be less extensive were being debated by G. Crile Jr 
[10] and B. Fisher [11] among others. In the beginning of the 1970s Umberto 
Veronesi (Italy) and Bernard Fisher (U.S.) initiated randomized studies 
comparing mastectomy with axillary dissection to breast-conserving surgery 
with axillary dissection followed by postoperative radiotherapy. These 
studies did not show any differences in survival. Due to these results the 
surgically standard practice for early breast cancer was changed to breast-
conserving surgery during the 1980s [12-15]. Concerning the removal of the 
axillary lymph-nodes it was seen that this gives prognostic information and 
aids in deciding when to carry out adjuvant treatment. It also prevents local 
tumour recurrences. However, if lymph-node metastases are absent, the 
benefit of axillary lymph node dissection (ALND) is low or non-existent. 
Axillary lymph-node dissection can generate more or less arm morbidity 
depending on the extent of the axillary surgery. During the 1990s the 
development of less extensive axillary surgery was started and studies using 
the sentinel lymph-node dissection (SLND) technique were initiated [16-18]. 
The sentinel node is the first lymph node that drains the tumour site. By 
injecting a tracer (a radioisotope or blue dye) in the tumour site the first 
lymph node draining this breast area can be detected and removed [19, 20]. 
The pathologist examines the lymph-node for metastases preoperatively and 
if it is free of tumours no axillary dissection is needed. The SLND reduces 
morbidity compared to ALND with equal risk of axillary recurrences [21, 
22]. 
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Today the standard breast cancer surgery is breast-conserving surgery. 
However, mastectomy is the treatment of choice if the tumour is > 4.0 cm, 
multifocal tumour, if mastectomy is preferred by the patient, or treatment of a 
recurrent tumour is indicated. Women with clinically detectable lymph-nodes 
should have an ALND but otherwise the SLND is the primary surgical 
procedure for management of the regional lymph-nodes. If the tumour in the 
breast is multifocal there is some uncertainty if ALND or SLND should be 
the primary axillary procedure. Giuliano et al showed in 2011 that SLND is 
as good as ALND even when lymph-node metastasis is present in women 
with early breast cancer [23] and this has also been supported by Galimberti 
et al in Milan [24]. Following these reports there has been a change in the 
opinion among the physicians towards the view that the axillary dissection 
often seems to be unnecessary and is almost considered an overtreatment. 
Umberto Veronesi has summarised the breast cancer treatment movement 
with the following phrase [25]. 
 
“ from the maximal treatment tolerable to the minimal treatment effective ” 
 
Endocrine Treatment 
The first endocrine treatment was done more than a century ago when George 
Beatson in 1896 described the remission of metastases after bilateral 
oophorectomy in women with advanced breast cancer. He was of course 
unaware of the anti-tumour mechanism mediated by the estrogen receptors 
(ER).  The estrogen receptors were first identified by Jensen et al [26] in 
1958 and ER are present in 70 to 80% of breast cancer tumours. The ER are 
intracellular receptors that are produced in most epithelial breasttissue cells 
and breast cancer cells. These receptors become activated by estrogen, which 
in turn activates proteins that are important to cell growth and mitosis. 
Tamoxifen, which was developed in the 1960s, acts as an ER-antagonist in 
breast tissue and thereby inhibits cell growth. However, Tamoxifen acts as an 
agonist in some tissues, e.g., in the endometrium which is the explanation of 
the increased risk of endometrial cancer among Tamoxifen-treated women. 
Cole et al published the first clinical trial with breast cancer patients in 1971 
where they showed a benefit among women with metastatic disease [27]. 
Ward et al [28] compared doses of Tamoxifen in 1973 and Stoll et al [29] 
introduced Tamoxifen in the adjuvant setting in 1976. Tamoxifen has 
relatively mild side effects and has become the most widely used systemic 
treatment of cancer in the world. The Early Breast Cancer Trialists' 
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Collaborative Group (EBCTCG) meta-analyses presented in 2011 show that 
five years of adjuvant Tamoxifen reduces the 15-year risk of breast cancer 
recurrence and death [30]. This advantage applies only to women with ER-
positive disease; women with ER-negative disease show no benefit from 
using Tamoxifen. Another possible approach to endocrine treatment is to do 
what Beatson did over 100 years ago, which is to stop estrogen production. 
The estrogen levels can be reduced by ovarian suppression in pre-menopausal 
women; either surgically with oophorectomy or medically by using 
luteinizing-hormone-releasing hormone (LHRH). Among post-menopausal 
women aromatase inhibitors (AI) stop the production of estrogen by blocking 
the enzyme aromatase, which turns androgen to estrogen in peripheral tissues 
of the body. 
 
Chemotherapy 
The development of chemotherapy started after World War II and single-
agent chemotherapy was first used when treating breast cancer. However, the 
first reports of benefits when using polychemotherapy came in the 1960s and 
70s [31-33]. One of the first established adjuvant chemotherapy combination 
was cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) [34, 35]. 
The treatment was further improved with the second generation of 
polychemotherapy that included anthracyclin. A known combination with 
anthracyclin is 5-fluorouracil, anthracyclin (epirubicin/doxorubicin), and 
cyclophosphamide (FAC/FEC) [36, 37]. The third generation of adjuvant 
chemotherapy was to introduce the use of taxanes and this resulted in an 
additional increase in the relative survival. In the first decade of the 21st 
century the first targeted drug, the HER-2 receptor antibody, trastuzumab, 
(except for endocrine treatment such as e.g. Tamoxifen) was added as a 
complement to chemotherapy. 
 
Radiotherapy 
Ionizing radiation has numerous effects of the cell. An important effect of 
ionizing radiation is damaging the DNA in the cell nucleus, and it does this 
whether the cell is a cancer cell or a healthy cell. It works either directly by 
causing a double-strand break in the DNA thereby causing cell-death or 
indirectly by ionizing the water in the cell to form hydroxyl radicals that can 
cause single-strand breaks. The single-strand breaks only cause sub-lethal 
damage to the DNA so the outcome will depend on the DNA repair capacity 
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of the cell. Cancer cells often have low DNA repair capacity while the cells 
in the normal tissue have a higher repair capacity.  
The history of radiotherapy starts in 1895 when W.C. Röntgen discovered x-
rays and continued with the discovery of radium and polonium by M. Curie 
in 1898. These discoveries resulted in the building of cancer hospitals around 
the world, one of which is Radiumhemmet (Stockholm) in 1910, which was 
equipped with 120 mg radium and an x-ray generator [38], and 
Jubileumskliniken (Gothenburg) in 1943. The SI unit Gray (Gy), named after 
the English physicist L.H. Gray, was first used in 1975. In the middle of the 
20th century, the use of radium in the field of radiotherapy was replaced by 
cobalt since cobalt has a much shorter half-life (5.27 y) than radium (1601 y). 
Cobalt-60 was the common radioactive source in external radiotherapy until 
the 1980s. The cobalt-machines were replaced during the 1980s and 1990s 
with linear particle accelerators (LINAC). The Linear accelerator uses high 
voltage and microwaves to accelerate electrons. In a collision of the electrons 
and a high Z material, high-energy photons are created. Thus the 
disadvantages of using an isotope – the steady decrease in activity which 
requires periodic replacement of the isotope and the condition that an isotope 
is continuously radioactive and cannot be powered off as can a LINAC - are 
avoided. In 1971 Godfrey Hounsfield invented the computed tomography 
(CT), which is fundamental in three-dimensional (3D) dose planning. Prior to 
the invention of CT, dose planning was based on two-dimensional (2D) x-
ray-images. Introduction of the use of CT made it possible to deliver the 
ionizing radiation in a more precise way to the target, thereby avoiding the 
surrounding normal tissue. During the 1980s and 1990s great progress was 
made and most oncology departments changed from using x-ray-images and 
hand-made 2D dose planning to using CT-images and computer-based 3D-
doseplanning. 
Between 1949 and 1954, the first randomised study was made of the long-
term effects of employing prophylactic x-ray therapy (kilo voltage machines) 
after radical mastectomy on patients with early breast cancer [39]. The 
follow-up showed no long-term survival benefit for the group with 
prophylactic x-ray therapy compared with the group not treated, so the author 
recommended that x-ray therapy not be used prophylactically. The early 
studies of radiotherapy showed that there were many undesirable side effects 
and that the survival benefits from treating the breast cancer with 
radiotherapy were outweighed by the risks of death from other causes [40]. 
During the past two decades, several studies have shown that radiotherapy 
reduces the risk of local recurrences by 60 to 70% but no single study has 
shown a survival benefit [41, 42]. However, the meta-analyses by the Early 
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Breast Cancer Trialists' Collaborative Group (EBCTCG) of postoperative 
radiotherapy following breast-conserving therapy (BCT) or following 
mastectomy in node-positive patients show a significant benefit in breast 
cancer-specific survival (+5.4% in absolute terms) and overall survival 
(+4.4% in absolute terms). The excess mortality (due to effects of 
radiotherapy) was mainly from heart disease and lung cancer. The breast 
cancer-specific survival remained unchanged but the overall survival 
increased to 5.3% when the oldest radiotherapy studies were excluded. 
However, studies using a shorter follow-up time most often underestimate the 
number of cardiac events. The EBCTCG concluded that, “about one breast 
cancer death over the next 15 years would be avoided for every four local 
recurrences avoided at 5 years”. For example, a reduction in the 5-year local 
recurrence risk of 12% would result in a 15-year reduction in breast cancer 
mortality of 3%, i.e. a 4:1 ratio [41]. In 2007 Bartelink et al [43] showed that 
a fractionated boost dose of 16 Gy to the original tumour bed led to improved 
local control in all age groups, with the largest benefit in young women, but 
with no difference in survival. Severe fibrosis was increased in the boost 
group. Results from randomised studies comparing hypofractionated 
radiotherapy with >2.0 Gy/fraction to conventionally fractionated 
radiotherapy with 2.0 Gy/fraction to 50 Gy have recently been published 
[44]. Whelan et al [45] presented 10-years of results comparing results using 
2.66 Gy to 42.5 Gy with the results from conventional fractionation and 
found similar results regarding tumour effect and normal tissue 
complications. START-A and -B (Standardisation of Breast Radiotherapy) 
[46, 47] compared results from conventional radiotherapy with those from 
3.2 Gy to a total dose of 41.6 Gy, 3 Gy to 39 Gy, and 2.66 Gy to 40 Gy but 
with a shorter follow-up. 
The recommendations by the Swedish Breast Cancer Group (SweBCG 
guidelines) are to use external radiotherapy to the breast after breast-
conserving surgery (BCS) and to the thorax after mastectomy if the tumour 
diameter > 5 cm or if regional radiotherapy has also been recommended. The 
standard irradiation schedule is 2 Gy per fraction, 5 days per week to a total 
of 50 Gy or a hypofractionation schedule (after BCS only) with 2.66 
Gy/fraction to a total of 42.5 Gy (> 50 years of age in Göteborg). An 
additional radiotherapy boost, of 16 Gy in 2 Gy-fractions, to the primary 
tumour site is recommended in young women (< 40 years of age) or if the 
tumour has not been removed radically. Regional radiotherapy to the axillary 
and the supraclavicular lymph nodes is recommended if > 4 lymph node 
metastasis are found or if >1 lymph node metastasis are found among women 
of < 40 years age, if the tumour is a grade III, has vascular invasion, or if the 
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ratio of number of lymph node metastasis divided by the number of examined 
lymph nodes is > 20%.  
 
1.2 Radiotherapy-related side effects in 
normal tissue 
The aim of radiotherapy is to kill the tumour cells without causing 
unnecessary damage to the normal tissue. Increasing the radiation dose 
increases the probability of killing the tumour cells (TCP, tumour control 
probability); however this will increase the probability of damaging the 
surrounding healthy tissue as well (NTCP, normal tissue complication 
probability).  The ratio between TCP and NTCP is the therapeutic ratio [48] 
and we always strive for a large ratio. The following section contains 
information regarding the side effects of radiation therapy.  
The side effects after radiotherapy are normally divided into two parts, the 
first part comprises the early side-effects that appear during or within weeks 
after radiotherapy, the second the late side-effects that appear months or 
years after treatment [49]. The side effects mainly develop locally in the 
irradiated tissue or organ, i.e. irradiation generally does not produce a 
systemic side effect as drug therapies do. The early side effects start to 
develop directly after treatment and are most readily apparent in tissues with 
rapidly proliferating cells, e.g. the skin, the haematopoietic system, or the 
gastrointestinal canal. The symptoms become apparent when mature cells 
that are lost due to normal tissue turnover are not replaced since the stem-
cells or precursor cells have been damaged [50]. Chemotherapy has a similar 
effect on the rapidly proliferating cells and this is why concomitant use of 
these two treatment modalities often leads to increased early normal tissue 
toxicity [51]. The early side effects are usually reversible as opposed to the 
late effects that tend to be irreversible. Ionizing radiation do not only cause 
cell killing but it also activate a cascade of cytokines as the transforming 
growth factor-β (TGF-β). Furthermore, radiation damages endothelial cells 
also activtes pro-fibrotic cytokines (as TGF-β). TGF-β seems to be important 
when explaining the radiation fibrosis that is a part of the late side-effects. 
Activation of TGF-β leads to increased extracellular matrix and collagen 
deposition. This radiation induced fibrogenic process is perpetuated over a 
long period of time [49]. 
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A universal link between early and late side effects has not yet been 
established [51, 52]. For some tissues such as the intestinal system and the 
mucosa there seems to be a relation but for others, e.g. the skin, it is less clear 
[53-55]. The response of normal tissue to radiotherapy cannot (so far) be 
predicted by in vitro tests [52, 56-58]. The explanation for this is probably 
that the in vivo situation is too complex with e.g. cytokine response and 
collagen deposition (i.e. concerted biological response) and cannot be 
mimicked in the laboratory [49, 59, 60].  
Organ-specific late side-effects 
A feared side late effect after breast cancer radiotherapy is the cardiotoxicity 
that has been known for decades [61]. The pathophysiology of radiation-
induced myocardial damage is mainly due to endothelial cell damage in 
microvessels, leading to perfusion defects and inflammatory infiltrates. 
However, radiation also damages the major arteries, leading to an accelerated 
development of atherosclerosis [62]. The risk has been most apparent when 
treating left sided breast cancers and if the internal mammary chain is 
included in the field [63-66]. With modern dose planning the cardiotoxic side 
effects seem to be decreased, but since the follow-up time to date has been 
shorter a lower incidence of cardiotoxicity is to be expected [41, 67-69]. In 
2011, McGale et al presented the incidence of heart disease in 35,000 women 
treated with radiotherapy for breast cancer in Denmark and Sweden [70]. 
They found that breast cancer radiotherapy has, at least until recently, 
increased the risk of developing ischemic heart disease, pericarditis and 
valvular disease. However, in the latest report from EBCTCG in 2011 the 
extra mortality due to cardiotoxicity seems to be very small (EBCTCG 2011). 
Dose-volume response analyses have been made, but so far no clear 
guidelines exits [71]. 
Often described late effects in breast radiotherapy trials comparing boost and 
hypofractionation are skin telangiectasia and fibrosis of subcutaneous tissue, 
which could lead to loss of volume and retraction of the breast [44-46, 53, 
72-74]. We know that increased doses to the breast, given as a boost, increase 
the risk of breast fibrosis [72, 75]. Pain in the breast area has been described 
as a late toxicity effect associated with radiotherapy, but the mechanisms 
behind this are not known [76-80].  
The risk of radiotherapy-induced brachial plexus neuropathy (BPN) has been 
reported since the late 1960s [81]. Brachial plexus neuropathy can result in 
paraesthesia, pain, and weakness of the arm. The pathophysiology of brachial 
plexus neuropathy is due to fibrosis of connective tissue around peripheral 
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nerves, damage to capillary blood vessels of the media of small arteries 
resulting in ischemia as well as extensive thickening of epi- and perineurium 
[82].  
Lung fibrosis is mostly associated with large lung volumes and concomitant 
chemotherapy. Clinical symptoms of lung fibrosis [46, 74, 83-85] are 
nonspecific and include e.g. cough, dyspnoea and fatigue. The underlying 
pathophysiology is similar to fibrosis that occurs in other tissues, with 
profibrotic cytokines, such as TGF-b IL-1 and IL-6, playing a role. 
Having had an axillary dissection instead of a sentinel node biopsy increases 
the risk for oedema in the arm, and the risk increases further when 
radiotherapy to the regional lymph nodes is added [83, 86, 87]. 
Rib fractures do not seem to be a significant problem after breast cancer 
radiotherapy, this side effect is more important after e.g. hypofractionated 
stereotactic radiation of lung cancer [46, 83, 85, 88-90]. 
Two important concluding summaries have been published, one by Emami 
[91] and the other by QUANTEC (Quantitative Analyses of Normal Tissue 
Effects in the Clinic) [92] in order to create clinical guidelines concerning 
tolerance doses of organs-at-risk.  
Of importance, although not within the scope of this thesis, are the secondary 
cancers due to breast cancer radiotherapy treatment; e.g. sarcoma [93], lung 
cancer [94], and contra lateral breast cancer [95]. The pathogenesis of 
secondary cancer is however linked to the mutagenic response of the ionizing 
radiation (e.g. if the DNA-damage is repaired incorrectly) rather than being 
derived from, e.g., the fibrogenic response. 
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2 Aim 
The overall aim of the research on which this thesis is based was to identify 
and quantify self-reported long-term symptoms/side-effects caused by breast 
cancer irradiation and to correlate these effects to patient and treatment-
related risk factors. Furthermore, we wanted to investigate how the dose-
volume distribution of ionizing radiation delivered to a certain anatomical 
volume contributed to the occurrence of a certain symptom, i.e. a dose-
volume response analysis. 
2.1 Specific Aims 
Paper I 
To compare the occurrence of eight pre-specified symptoms/side-effects 
groups (below) among women who were randomised to receive tangential 
breast irradiation or not after breast conserving surgery with axillary 
dissection due to breast cancer 10 to 17 years earlier. 
With decreasing likelihood, we hypothesised that radiation would induce:  
1 - pain in the breast,  
2 - oedema in the breast or the upper limb,  
3 - disturbances of skin sensation on the breast,  
4 - erysipelas in the upper part of the body,  
5 - symptoms from the heart,  
6 - symptoms from the lungs,  
7 - fractures in the ribs, and  
8 - decreased shoulder or arm mobility.  
 
 
Dan Lundstedt 
 
 15 
Paper II 
Based on the results in paper I and from the literature we know that 
radiotherapy increases the risk of long-term breast pain. In this paper we 
investigate risk factors that could increase the risk of reporting breast pain 
among women who received irradiation after breast conserving surgery 3 to 
17 years earlier.  
Paper III 
In this paper we wanted to investigate if modern standard radiotherapy, i.e. 
3D dose planning and 2.0 Gy fractionation to the regional lymph-nodes, 
resulting in radiotherapy fields covering the nervous plexus brachialis, 
increases the risk of reporting neuropathy 3 to 8 years later.  
Paper IV 
Based on the results in paper III and from the literature we know that regional 
radiotherapy increases the risk of paraesthesia. In this paper we investigated 
dose-volume predictors after irradiation of the plexus brachialis for the 
development of paraesthesia among breast cancer patients.  
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3 Patients and Methods 
3.1 Patients 
Cohort 1 
From 1991 through 1997, 1187 women participated in the multi-institutional 
SweBCG91-RT (Swedish Breast Cancer Group 1991-RadioTherapy trial). 
Women with stage I-II lymph node-negative breast cancer (T1-2N0M0) who 
had been treated with breast conservation and axillary dissection were 
randomly assigned either to a group receiving no further treatment or to a 
group receiving postoperative radiotherapy. We included women from the 
SweBCG91-RT trial who lived in the West and South health-care regions. 
The third and last health-care region, Uppsala-Örebro, only included 43 
women. These were excluded for cost-efficacy reasons. To increase the 
quality of the data and to ensure a high participation rate, we included women 
born in 1931 or later. We excluded women who had died, had a breast cancer 
recurrence, had a cancer treatment during 2007, did not speak Swedish, or 
were not living in Sweden. After exclusion we identified 422 women (Figure 
1).  
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Figure 1: A flowchart of cohort one, i.e. the patients included in the SweBCG91-RT trial, presented 
according the intention-to-treat (ITT). Women with breast cancer who had a breast conserving surgery 
and axillary dissection were randomised to receive or not to receive postoperative radiotherapy. 
 
       
 
 
 
 
 
 
SweBCG 91-RT  
(n=1187) 
 
Non-radiotherapy (Surgery 
only) (n=594) 
Radiotherapy (Surgery and   
radiotherapy) (n=593) 
 
Excluded (n=509): 
 
Not meeting inclusion criteria 
(n=9) 
Born 1930 or earlier (n=457) 
Örebro healthcare region (n=43) 
Assessed for eligibility 
(n=678)  
 
 Non-radiotherapy (n=341) 
 Radiotherapy (n=337) Excluded (n=256): 
 
Death of any cause or had a 
breast cancer recurrence (n=246) 
Cancer treatment at 2007 (n=8) 
Not Swedish speaking (n=1) 
Moved abroad (n=1) 
Allocated to participation, 
non-radiotherapy (n=201) 
Allocated to participation, 
radiotherapy (n=221) 
Analysed, radiotherapy  
(n=194) 
Analysed, non-radiotherapy 
(n=171) 
Nonparticipants (n=27): 
 
 Refused to participate (n=16) 
 Not reachable (n=10) 
 Excluded by mistake (n=1) 
Nonparticipants (n=30): 
 
 Refused to participate (n=19) 
 Not reachable (n=6) 
 Excluded by mistake (n=5) 
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Cohort 2 
Through medical records we identified the women who had breast cancer 
radiotherapy based on a 3D-dose plan between mid-1999 and 2004 at 
Sahlgrenska University Hospital, Gothenburg. At the Sahlgrenska University 
Hospital, we started to use 3D-dose planning for all our breast cancer 
treatments from mid-1999 and onwards. During the time period 1999 to 
2004, 2565 women were consecutively registered as treated with 
radiotherapy due to a primary breast cancer in Gothenburg. Among these 
treatments, we were unable to reactivate 130 archived dose plans due to 
technical reasons. To ensure a high participation rate we excluded women 
born in 1930 or earlier (n=263). We also excluded women who had died, had 
a breast cancer recurrence, had another radiotherapy treatment registered, had 
a cancer treatment during the last year (i.e. 2007/08), had not completed the 
planned radiotherapy treatment, suffered from dementia, did not speak 
Swedish or who were not living in Sweden (n=396). Of the 2565 women we 
identified 1776 eligible women. Of these 1776 women, 1372 women had the 
most common treatment with breast-conserving surgery followed by 
postoperative tangential breast irradiation without any boost or regional 
radiotherapy. Due to cost-efficacy considerations we randomly excluded half 
(685 excluded out of 1372) of the women with the most common treatment. 
Thus there were 1091 women remaining for the study (Figure 2).  
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Figure 2: A flowchart of cohort two, i.e. the patients who had breast cancer radiotherapy 
treatment between 1999 and 2004 at Sahlgrenska University Hospital, Gothenburg. 
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study (n=685)   
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Breast cancer recurrence 
(n=23) 
Cancer treatment at 2007/08 
(n=6) 
Inadequate radiotherapy 
(n=1) 
Assessed for participation  
(n=1091) 
  
Analysed (n=930) 
Responded questionnaire 
 
Non-responders (n=131) 
 
 
Consecutively treated in Gothenburg 
1999 to 2004 (n=2565) 
Not meeting inclusion criteria 
(n=789) 
- No 3D dose info (n=130) 
- Born before 1931 (n=263) 
- Death, reccurrence (n=396) 
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Patients in paper I 
In paper I we analysed the data from the women in cohort one according the 
intention to treat (ITT). Non-radiotherapy (n=171) and radiotherapy (n=194), 
in total n=365 women. 
Patients in paper II 
In paper II we analysed the data from the women with breast-conserving 
surgery with radiotherapy in cohort one and two. The women that had 
radiotherapy from cohort one were included according received treatment and 
not according ITT. Five women in cohort one had not received treatment 
according to ITT, and of these five, three did not receive their radiotherapy as 
intended and two received radiotherapy that they should not have received 
(n=194–3+2=193). The women from cohort two (n=930) that had a breast 
conserving surgery were included (n=684) and the women that had had a 
total mastectomy were excluded (n=246). In total 193 + 684 = 877 women. 
Patients in paper III 
In paper III we analysed the data from the women in cohort two. Of these 930 
women, 111 had had the older 2.4 Gy fractionation schedule and were 
excluded. Five more women were excluded because we lacked information 
about whether axillary dissection had been performed. Of the remaining 814 
women, 192 women had had axillary dissection and regional radiotherapy, 
509 women had had axillary dissection without regional radiotherapy, and 
113 women had had neither axillary dissection nor regional radiotherapy. 
Patients in paper IV 
In paper IV we analysed the data from the women in cohort two that had 
axillary dissection with regional radiotherapy in 2.0 Gy fractions (n=192) and 
used women that had axillary dissection without regional radiotherapy as a 
reference group (n=509).  
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3.2 Treatments 
3.2.1 Surgery and Radiotherapy 
The women underwent breast-conserving surgery or mastectomy with an 
axillary lymph node dissection of level I and II or a sentinel lymph node 
biopsy. Radiotherapy was given either 4 days a week over 5 weeks, 2.4 Gy 
per fraction, to a total target dose of 48 Gy or 5 days a week over 5 weeks, 
2.0 Gy per fraction, to a total target dose of 50 Gy. In addition, women with 
four or more axillary lymph node metastases also received regional 
radiotherapy i.e. radiotherapy to the supra/infraclavicular lymph nodes and 
the level III axillary lymph nodes. The lymph nodes were treated with 46 to 
50 Gy, given in 2.0 Gy fractions per day. Young premenopausal women 
received an additional boost to the primary tumour site of up to 16 Gy, given 
in 2.0 fractions per day. The patient had a supine treatment position.  
Cohort one: The target was defined as the remaining breast parenchyma, 
without the regional lymph nodes. The treatment fields had a margin of 1–2 
cm with respect to the breast parenchyma and were also limited to the 
ipsilateral breast, not crossing the medial line. This treatment technique 
limited the volumes of lung and heart receiving full dose. No bolus was used. 
The dose-specification point was defined at the centre of the target volume. 
The minimum and maximum doses in the target volume were defined 
according to the International Commission on Radiation Units and 
Measurements [96] and should have been within 93–110% of the specified 
dose. All patients had individual computerised dose planning with wedge 
compensators used to achieve a uniform dose. At one of the departments a 
two-dimensional planning technique, based on three CT slices, was used 
throughout the whole study period. At the other three departments the same 
two-dimensional technique was used in the first year, but by 1993 all women 
had three-dimensional dose planning (TMS, Helax AB) based on multiple CT 
slices with intervals of typically one centimetre. 
Cohort two: All patients had three-dimensional dose planning (Varian 
Medical Systems Inc., Eclipse/Cadplan) based on CT scanning with slice 
thickness of 5 to 10 mm. For women without regional treatment the PTV 
(Planning Target Volume) included the remaining breast/thoracic wall 
(Figure 3,4). Tangential photon beams or an electron beam was used having 
the isocenter located centrally in the breast/thoracic wall. For women with 
regional treatment the PTV included the breast/thoracic wall and 
supraclavicular fossa/the top of the axilla (level III) (Figure 5). A common 
isocentre for all fields was located in the junction between the supraclavicular 
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fossa/the top of the axilla fields and breast/thoracic wall fields. A high-energy 
linac with dual photon beams and electron beams was used. All treatment 
plans were individually optimized. The supraclavicular fossa/the top of the 
axilla volume was planned with opposed fields; AP (anterior-posterior) field 
of 6 MV (megavolts) with a relative beam weight of about 1.0, PA (posterior-
anterior) field of 15 MV with a relative beam weight of about 0.4. The dose 
was prescribed in the centre of the supraclavicular fossa/the top of the axilla 
part of the PTV and normalized to this point. The maximum dose was 105 to 
108 % (specified as percentage of prescribed dose) and located about 1 cm 
below the skin (not in isocentre plane). The breast was planned with 
tangential 6 MV photon beams tilted 5 to 10 degrees in order to minimize 
divergence of the fields. The dose was prescribed in the centre of the breast 
and normalized to this point. The thoracic wall had either tangential fields or 
a combination of electron and photon beams. The electron beam had the same 
isocentre as the other fields. In the isocentre plane between the electron beam 
and the supraclavicular fossa/the top of the axilla fields the maximum dose at 
1 to 2 cm below skin was usually 110 % (accepted range up to 115 %). A 
bolus of typically 5 mm to increase the superficial dose was always used after 
mastectomy but was generally not used after breast-conservation except in 13 
patients with superficial tumours. 
 
 
 
 
 
 
 
 
 
Figure 3: A left side breast cancer treatment plan, shown in a transverse plane. 
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Figure 4: The figure shows a reconstructed coronal view. Left side breast PTV (blue) and CTV (red). 
Organs at risk: Lung (green) and heart (yellow lines).  
Figure 5: The figure shows a 
reconstructed coronal view. Left 
side thorax PTV (blue) includning 
regional lymph nodes. Organs at 
risk: Lung (green) and heart 
(yellow).  
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3.2.2 Systemic treatments 
The recommendations in the SweBCG91-RT trial were that women with an 
estrogen receptor-positive tumour with a diameter of more than 2 cm should 
receive endocrine treatment (Tamoxifen) and that premenopausal women 
with an estrogen receptor-negative tumour of more than 2 cm should receive 
chemotherapy (cyclophosphamide, methotrexate, fluorouracil). In practice 
very few of the women in the SweBCG91-RT trial had any systemic 
treatment since they had an early breast cancer without lymph node 
metastases. 
The women in cohort two were treated according to regional healthcare 
guidelines. Chemotherapy (cyclophosphamide, methotrexate, and 
fluorouracil or fluorouracil, epirubicin, and cyclophosphamide) indications 
for premenopausal and postmenopausal women were either one of:  
1 – Lymph-node metastases or 2 – Two of the following if N0; a primary 
tumour diameter of more than 2 cm or endocrine receptor-negative tumour or 
S-phase ≥12%.  
Generally, women with a receptor-positive tumour received endocrine 
treatment (Tamoxifen). Older postmenopausal women received an individual 
treatment plans based on their physical status.  
 
 
3.3 Methods 
3.3.1 Development of questionnaire 
We were interested in learning whether or not the breast cancer-irradiation 
caused women problems many years after treatment. Our intention was to 
achieve the self-assessed, not physician-assessed, descriptions of symptoms 
and if these symptoms affected daily life. We wanted to develop the 
questionnaire from the beginning, based on semi-structured interviews, since 
we wanted to create a wider picture and to cover aspects in addition to those 
in current questionnaires [97-100]. We intended to collect all information 
regarding the symptoms/side effects that the women experienced in their 
daily life years after treatment. The ambition was to create a questionnaire in 
which one question represents one phenomenon, instead of the more common 
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questionnaire where the items are summarized to global scores and 
represented with a number. The development of the questionnaire was done 
according to the established procedures at the Division of Clinical Cancer 
Epidemiology [101-104]. 
Interviews 
The qualitative phase lasted approximately 1.5 years and was the foundation 
of the study. We interviewed women that had undergone breast cancer 
surgery and postoperative radiotherapy three to 20 years earlier, 1985 to 
2003. The women were first contacted by mail and asked if they were willing 
to participate in an interview. A few days after the first contact, each woman 
was contacted again by phone and asked if she would be willing to 
participate. Those who volunteered were interviewed primarily in their home 
or otherwise at the research unit. The interviews were recorded and 
performed in a semi-structured way by focusing on the informant’s present 
situation, current symptoms, effects on daily life, social functioning and 
coping strategies. The goal was to continue interviewing until no new 
information was identified (saturation) and in total 22 women shared their 
experiences. A secretary continuously prepared word-by-word transcripts 
from the interview recordings. 
Questionnaire 
Based on interviews, our clinical knowledge, and the literature a 
questionnaire was constructed. The different themes, sorted into specific 
areas, were formulated into questions and divided into sections. We 
developed questions asking about symptoms on both the left and the right 
side of the body, i.e. both the treated side and the opposite part of the body. 
In the analysis phase we used the answers from the treated side. We also 
included questions asking if these symptoms affected daily life. When 
formulating the questions we aimed at using the words/phrases that the 
women used during the interviews. Information on variables reflecting 
potential confounding and effect-modifying factors such as concurrent 
diseases and treatments were also collected. The questionnaire was extensive 
and consisted of 240 questions that were arranged in the following sequence 
 
1. Breast cancer treatment. Surgery, radiotherapy, chemotherapy, 
endocrine treatment and disease recurrences: questions 1.1-1.11 
2. Psychological issues and wellbeing: questions 2.1-2.12 
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3. Mobility and strength: questions 3.1-3.27 
4. Oedema: questions 4.1-4.66 
5. Pain: questions 5.1-5.101 
6. Paresthesia: questions 6.1-6.5 
7. Breast reconstruction: questions 7.1-7.5 
8. The throat: questions 8.1-8.12 
9. Heart and lungs: questions 9.1-9.25 
10. The skin: questions 10.1-10.23 
11. Sexuality: questions 11.1-11.5 
12. Education, martial status, co-morbidity: questions 12.1-12.33 
13. Evaluating the perception of participation: questions 13.1-13.8 
 
We inquired about the frequency and intensity of a symptom when 
appropriate. For example: Have you felt pain in your left breast in the 
previous six months? The answer category was: “No”, “Yes, on occasion”, 
“Yes, at least every month”, “Yes, at least every week”, “Yes, at least three 
times every week”, “Yes, every day”. In addition, there was space for 
supplementary comments within each section. For evaluating the perception 
of participation seven questions were included. For example: Do you believe 
it is valuable to conduct a study like this? “No, not at all”, “Yes, somewhat”, 
“Yes, moderate”, “Yes, much”. 
Face-to-face validation 
At this stage, to ensure that all questions and response alternatives were fully 
understood, an investigator accompanied women treated for breast cancer 
while they filled out the questionnaire, i.e. face-to-face validation. This led to 
the formulation of new versions and the process continued until the 
participants suggested that the questions covered all their experienced 
symptoms and was easily understood. The questionnaire was tested for face-
to-face validation on totally 20 women.  
Pilot study 
In a pilot study comprising 32 women treated for breast cancer we estimated 
a likely participation rate and whether or not the women would leave certain 
questions unanswered. After receiving 30 of 32 questionnaires we proceeded 
to the main study. The Regional Ethic Committee in Gothenburg approved of 
the study. 
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Data collection 
From October 2007 to April 2008, an introductory letter was sent to the 
women explaining the objects of the study emphasizing that participation in 
the study was voluntary. Three days later an interviewer phoned each 
informant. Those giving informed oral consent to participate received a postal 
questionnaire along with a letter and additional information. Ten days later, a 
thank-you card was sent to show appreciation or to serve as a reminder. 
Fourteen days later an interviewer called those who had not returned the 
questionnaire, giving the women the opportunity to ask questions or decline 
further participation. To ensure anonymity the questionnaires were coded, 
making it possible to match responses to the treatment given.  
Data entry 
Transfer of all data from the questionnaire answered by cancer survivors was 
performed using the freeware data and validation program EpiData 3.1 
(www.epidata.dk). 
Treatment plan reactivation 
At Sahlgrenska University Hospital, Gothenburg, we started to use 3D-
treatment planning for all breast cancer treatments from the 1999 onward. In 
our study we reactivated the treatment plans and made copies that we used to 
investigate how the dose-volume distribution of ionizing radiation delivered 
to a certain anatomical volume had contributed to the occurrence of a certain 
symptom, i.e. a dose-volume response analysis. 
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3.3.2 Delineation of the brachial nerve 
The patient had a supine treatment position. An individual vacuum form 
connected to an arm holder was made with the intent of having the sternum 
as nearly horizontal as possible. The patient had to hold the arm on the 
treatment side on the holder beside the head. The contralateral arm was 
placed along the body. Together with a radiologist we modified the 
guidelines regarding contouring of the brachial plexus by Hall et al and 
applied them to breast cancer patients with an elevated ipsilateral arm. To 
contour the brachial plexus we used a 5-mm diameter paint tool. The 
contouring started at the neural foramina from C5 to T1 and the delineation 
extended from the lateral border of the spinal canal to the space between the 
anterior and middle scalene muscles. If the neural foramen was lacking on the 
CT slice the space between the anterior and middle scalene muscles was 
delineated. Further contouring went between the first rib and the clavicle, 
behind the minor pectoral muscle (following the subclavian artery when 
possible), below the coracoid process and in front of the subscapularis muscle 
(Figure 6,7).  
Figure 6: Reconstructed coronal view of the delineated brachial plexus. 
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3.3.3 Statistical analyses 
To gain a pedagogic clarity the outcome variable was often dichotomized. 
The results are presented as relative risks (RR). We adjusted these relative 
risks, when suitable, using the SAS procedure GENMOD (SAS version 9.2; 
SAS Institute Inc., Cary, NC) with binomial distribution and logarithmic link 
function. The relative risks were considered as 'statistically significant' when 
the 95% confidence interval (CI) did not contain 1.00, i.e. the reference 
value. See manuscript I-IV for details of statistically analyses of each study. 
 
 
 
Figure 7: Dose Volume Histogram (DVH) of a delineated brachial plexus. 
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4 Results 
Paper I: 
Of the 422 eligible women 365 (86%) returned the questionnaires. 
Participation rates were similar for both groups (BCS+RT 194/221 [88%] vs. 
BCS 171/201 [85%]). Five women who completed the questionnaire had not 
received treatment according to randomisation (the intention-to-treat). Three 
women did not receive their radiotherapy as intended and two received 
radiotherapy that they should not have received. In the analyses, the results 
were identical or similar whether these women were included or not. The 
results are presented according to the intention-to-treat. Mean age when 
completing the questionnaire was 67 years and the mean time since treatment 
was 14 years. The tumour characteristics were closely similar in the two 
groups as well as in comparison to the original study group with 1187 
women. 
For six symptom groups (oedema in breast or arm, erysipelas, heart 
symptoms, lung symptoms, rib fractures, and decreased shoulder mobility) 
we found a similar occurrence in both groups.  
However, the first hypothesis that radiation would induce breast pain was 
confirmed. In the group with postoperative radiotherapy 35.8 percent 
reported occasional pain in the treated breast compared to 19.9 percent in the 
non-radiotherapy group with an absolute difference of 15.9 percent, RR 1.80 
(95% CI 1.26-2.57). Corresponding figures for occurrence at least once a 
Figure 8: Occurrence presented by each response category. The figure shows the absolute 
percent based on all women in each group, but shows only the women who answered yes. 
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week were 8.8 percent versus 0.6 percent with an absolute difference of 8.2 
percent, RR 15.1 (95% CI 2.03-112). Touching and pressure on the treated 
breast were reported to induce breast pain more often in the irradiated group. 
Examining other cut-off points did not alter the results in a way that would 
lead to an alternative interpretation of effects (Figure 8). Analyses restricted 
to women who did not have chemotherapy showed similar results. 
The third hypothesis regarding disturbances of skin sensation was also 
confirmed. The irradiated group reported a higher occurrence of 
hypersensitivity in the skin on the treated breast, 5.2% versus 0.6% in the 
surgery only group, RR 8.81. The adjusted relative risk resulted in estimates 
ranging from 7.92 to 8.83. Sensitivity to sun exposure on the treated side, 
compared to the contra lateral breast, was more common in the irradiated 
group, 7.3% versus 1.2%, RR 6.33. In the group with postoperative 
radiotherapy 21.9% reported occasional pain in the skin compared to 11.8% 
in the non-radiotherapy group with an absolute difference of 10.1 percent, RR 
1.86 (95% CI 1.14-3.04). 
We found no statistically significant differences between the groups for 
whether symptoms affected daily life or the use of analgesics.  
 
- I have not been able to wear a bra for many years due to discomfort.  
  Radiotherapy, 16 years ago.  
- It is not easy to find a comfortable bra since my breast always aches or 
hurts.      Radiotherapy, 11 years ago. 
 - If I am hit in my breast, even if not very hard by an elbow, for example, it 
hurts a lot.    Surgery only, 10 years ago.  
- My breast has been aching since 1996.  Radiotherapy, 11 years ago.  
- When I wear thin clothing in the sun it burns like fire in the skin on my 
breast.    Radiotherapy, 13 years ago.  
- The skin on my breast burns or stings when I am in the sun wearing thin 
clothing.    Radiotherapy, 15 years ago.  
- During the years since being treated, I have learned to adapt and to cope 
with the pain and discomfort that the surgery and radiotherapy caused me.  
   Radiotherapy, 14 years ago. 
 
 - …but this is not so important since I have been cured of cancer.   
 Various women. 
Figure 9: A sample of comments in the questionnaires written by the women in cohort one. 
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Paper II 
We received 193/221 (87%) questionnaires from the women in cohort one 
and 684/806 (85%) questionnaires from the women in cohort two. In total 
877/1027 (85%) of the women had returned their questionnaire. Of these, 873 
women answered the question in the questionnaire regarding breast pain. The 
mean age at treatment was 55 years, range 28 to 73 years. The occurrence of 
breast pain at least every week among the 873 women in this study who had 
breast-conserving surgery and radiotherapy was 13.2%, three to 17 years 
after treatment.  
Among women with breast pain 30% consumed analgesics every week 
compared to 9% among women without weekly breast pain (RR 3.5; 95% CI 
2.5-5.1). Furthermore in the group with breast pain, discomfort and pain 
resulted in: affected wellbeing (RR 4.6; 95% CI 3.3-6.4), sleeping trouble 
(RR 4.7; 95% CI 3.3-6.5), avoidance of wearing a bra (RR 4.0; 95% CI 2.7-
5.7), discomfort due to tight clothing (RR 3.2; 95% CI 2.6-4.0), difficulties 
buying fitting clothing (RR 3.5; 95% CI 1.7-7.3), and affected daily activity 
(RR 4.1; 95% CI 2.9-5.9). 
There was a statistically significant relation between younger age and a 
higher occurrence of breast pain (Figure 10). Among women up to 39 years 
of age at treatment, 23.1% experienced pain in the breast at least every week, 
compared to 8.7% among women older than 60 years, giving an absolute 
difference of 14.4% (RR 2.66; 95% CI 1.33-5.36). The annual relative risk 
reduction was 0.96 (95% CI 0.94-0.98). When we examined the time since 
treatment we found that there was a statistically significant relation to breast 
pain. Women for whom a longer period of time had passed since treatment 
reported breast pain significantly less often than did the other women. The 
occurrence of breast pain was reported with the lowest frequency, 8.8%, 
among women treated more than a decade earlier and the highest, 15.5%, 
among women treated three to five years earlier (RR 1.75; 95% CI 1.05-
2.93). The annual relative risk reduction was 0.93 (95% CI 0.88-0.98). 
Chemotherapy increased the risk of having breast pain from 11.7% to 20.1% 
(RR 1.72; 95% CI 1.19-2.47). However, in the multivariable model only age 
at treatment and time since treatment were statistically significantly related to 
the occurrence of breast pain. In the multivariable model chemotherapy did 
not increase the risk of reporting breast pain.   
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No statistically significant associations were found between the two different 
radiotherapy fractionation schedules with 2.4 Gy to 48 Gy or with 2.0 Gy to 
50 Gy and the occurrence of breast pain (RR 0.85; 95% CI 0.54-1.36). There 
was no significant relation to breast pain regarding the other potential effect 
modifiers; endocrine treatment, tumour size, photon energy, radiotherapy 
boost, regional radiotherapy to the lymph nodes, axillary dissection, 
overweight, smoking, marital status, parity, and level of education. 
Paper III 
We received 930/1091 (85%) questionnaires. Of these 930 women, 111 had 
had the older 2.4 Gy fractionation schedule and were excluded. Five more 
women were excluded because we lacked information about whether axillary 
dissection had been performed. Of the remaining 814 women, 192 women 
(24%) had had axillary dissection and regional radiotherapy, 509 women 
(62%) had had axillary dissection without regional radiotherapy, and 113 
women (14%) had had neither axillary dissection nor regional radiotherapy. 
The median age at treatment was 55 years (range 28–73) and the median time 
since treatment was 5 years (range 3–8 years). The concurrent diseases 
diabetes, rheumatoid arthritis, and stroke were not more frequent in the group 
with axillary dissection and regional radiotherapy than in the other two 
groups. 
 
 
 
Figure 10: 
Breast pain 
occurrence by 
age group. 
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Regional radiotherapy, paraesthesia, and oedema 
In the group with axillary dissection and regional radiotherapy 20% reported 
paraesthesia compared with 13% in the group with axillary dissection only 
(RR 1.47; 95% CI 1.02–2.11). The corresponding figures for oedema were 
22% and 15%, (RR 1.46; 95% CI 1.04–2.03). The relative risk of reporting 
paraesthesia after radiotherapy becomes 1.28 (95% CI 0.93-1.76) when 
adjusted for oedema. We found no relation between time since treatment and 
the occurrence of paraesthesia after regional radiotherapy. More than half 
(61%) of the women with paraesthesia after axillary dissection and regional 
radiotherapy reported that this symptom affected their well-being moderately 
to much. The women with neither axillary dissection nor regional 
radiotherapy reported the lowest occurrence of paraesthesia 8% and oedema 
5%. 
Having had mastectomy versus breast conserving surgery did not 
significantly contribute to paraesthesia (RR 1.13; 95% CI 0.78–1.63). Neither 
the number of examined axillary lymph nodes (RR 1.02; 95% CI 0.99–1.04) 
nor having had chemotherapy contributed significantly to paraesthesia (RR 
1.29; 95% CI 0.91–1.83). Among the women 49 years of age or younger with 
axillary dissection and regional radiotherapy, 26.8% reported paraesthesia 
(RR 2.45; 95% CI 1.05–5.73); among women 50–59 years of age 19.7% 
reported paraesthesia (RR 1.81; 95% CI 0.73– 4.44), compared with only 
10.9% of women over 59 years of age (RR 1.00 Reference) (Figure 11). 
 
 Pain and decreased strength 
We found no statistically significant differences in reporting pain in the arm, 
the use of analgesics, or decreased strength between having had both axillary 
dissection and regional radiotherapy and having had axillary dissection only. 
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Figure 11: Presenting the percentage of women with paraesthesia in the three different treatment 
groups as well as in age groups. The women who had regional radiotherapy have a more apparent 
relation between age and paraesthesia than the women in the other two groups.  
*Numbers of women with paraesthesia and the total number of women in each age group. 
†The median number of examined lymph nodes is shown within parantheses for each age group. 
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Paper IV 
The following three possible dose-volume predictors were investigated in 
relation to paraesthesia:  
1 – V40Gy (volume), i.e. the delineated volume of the brachial nerve in cm3 
that received at least 40.0 Gy. Due to the relatively large thickness of the CT 
scanning slices, 5 to 10 mm, we chose to investigate the V40Gy instead of a 
higher dose that would only have represented a few but highly unreliably cm3 
and thereby would have contributed a large uncertainty concerning the 
results. The women were divided into three numerically equal groups, < 11.3 
cm3, 11.4 – 13.4 cm3, and > 13.5 cm3. Among the women receiving regional 
radiotherapy with V40Gy >13.5 cm3 25% reported paraesthesia, resulting in a 
significantly RR of 1.83 (95% CI 1.13-2.95) (Figure 12). The risk was still 
significant after adjustment for oedema (RR 1.64; 95% CI 1.12-2.41) (Figure 
13). V40Gy below 13.5 cm3 showed no significant relation to paraesthesia. 
2 – The maximum dose within the delineated volume. The calculation grid 
size was 5x5x5 (- 10) mm (depending on the CT slice thickness), that is 
different voxels represents different volumes 0.125 or 0.25 cm3. The women 
were divided into three groups, < 50.0 Gy, 50.1 – 54.9 Gy, and > 55.0 Gy. 
Women having maximum dose in plexus brachialis of >55.0 Gy (n=12) had 
an occurrence of 25% with the highest RR 1.86, however this was not 
significant and had a wide confidence interval (95% CI 0.68-5.07). The 
corresponding risk after adjustment for oedema was RR 1.54 (95% CI 0.70-
3.40). 
3 – The prescribed doses 46 or 50 Gy, to the regional lymph nodes. When 
evaluating the prescribed doses 46 and 50 Gy, the occurrence of paraesthesia 
was 21 and 18% with unadjusted RRs of 1.60 (95% CI 1.04-2.44) and 1.34 
(95% CI 0.81-2.23). However after adjusting for oedema, it was not 
significant RR 1.27 (95% CI 0.87-1.83) and RR 1.32 (95% CI 0.85-2.05). 
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Figure 12: Percent of women reporting paraesthesia in the hand. Presented in subgroups 
representing various dose-volume aspects. 
Figure 13: The relative risks of reporting paraesthesia in the hand adjusted for oedema. The women 
that did not receive regional radiotherapy represent the reference group, 1.00. The subgroups are 
representing various dose-volume aspects. N.B. the y-axis starts at 0.8. 
% 
adjRR 
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5 Discussion 
5.1 Methodological considerations 
In real life it is not possible to carry out an error-free study. All studies 
include errors, either a systematic error which can introduce bias to the 
effect-measure, or a random error which can influence the precision of the 
effect-measure of the study. In our research group, we used epidemiological 
methods as applied by the hierarchical step-model for causation of bias with 
the aim of identifying and minimizing the possible sources of bias in the 
effect-measure in a study [101]. According to the hierarchical step-model, 
each step of the research process introduces a special source of error. The 
model depicts how a real-life study (such as ours) deviates from “the perfect 
study” and proceeds in four steps towards a calculated, often adjusted, effect-
measure (Figure 14).  
 
  
 
Step 1: Confounding 
A confounding factor may produce a spurious association between the 
studied variables when no real association between them exists. If 
confounding factors are neither measured nor considered, results may be 
biased. To be defined as a confounding factor, the factor must be both 
associated with the exposure (in our study, radiotherapy) and be an 
independent risk factor for the outcome (in our study, long-term symptom). 
Figur 14: The hierachical step-model for causation of bias. * Total bias from the perfect person time to 
the adjusted effect-measure. 
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When confounding factors are not taken into account, the effect-measure may 
over or under estimate the true association between exposure and outcome. 
In our study, preventative measures were taken in the preparatory phase to 
avoid systematic errors due to confounding factors. Since breast cancer is 
much more common among women than among men, we focused only on the 
women and we did therefore not have to take gender into account as a 
possible confounder. We excluded women with cancer recurrences since this 
could cause e.g. pain or neuropathy. We collected as much information as 
possible on other confounding factors, either through the questionnaires of 
through medical records. Information assessed from cancer survivors 
included; age, education, smoking, BMI, medications, marital status, parity, 
co-morbidities such as diabetes mellitus, neurological diseases, 
cardiovascular diseases (e.g. stroke, hypertension, ischemic heart disease).  
From medical records we collected data on diagnosis, stage of disease, 
treatment modality, recurrence and radiotherapy doses. Known or suspected 
causal factors for the outcome studied were taken into account in our 
analyses. 
Step 2: Misrepresentation 
In the second step of the hierarchical step-model, bias due to non-
representation and selection-introduced problems is introduced, since this 
reveals a difference between the targeted person-time and the observed 
person-time. The study was well grounded in the initial qualitative phase with 
validation of the instrument and the method being tested in a pilot study 
within the study-population to make sure that we could continue to the 
quantitative phase and collect data.  
Non-participants induce loss of information from the targeted person-time 
and therefore it is crucial to avoid non-participation. The participation rate 
was assessed in a pilot study before moving on to the main study. The 
participation rate in the pilot and main studies was high, 94, 85 and 85 
percent respectively for the pilot, cohort 1 and 2. A description of our method 
of collection data, including an informative introduction letter sent to all 
participants and following introductory telephone call, has been described in 
the chapter on Method. We believe that working intensely in the initial phase 
of data collection can partly explain our reasonably high participation rate, 
thereby minimizing risk of selection-induced problems. 
We can only speculate if non-participants for whom we have no information 
belong to the healthier part of the population or the less healthy.  We cannot 
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overrule the possibility that those who did not participate were somehow 
different than participants which might influence our results. 
Step 3: Misclassification 
According to the hierarchical step-model for causation of bias, the third step 
of a study may introduce bias when the information collected is incorrect for 
some reason. Therefore, an important part of each study is the instrument. In 
developing our instrument, we began by performing semi-structured 
interviews with the target population (breast cancer survivors). During the 
interviews they were all given the chance to talk about their personal 
experience and the challenge that can arise in their new life situation after a 
cancer treatment. The interviews proceeded with additional cancer survivors 
until we did not gain any new information (saturation). The development of 
the study-specific questionnaire was therefore founded in the interviews, our 
clinical knowledge and in the literature.  
An important task was to make all questions clear and understandable. Face-
to-face validation within the study-population led to modifications, new 
drafts were developed and validated. We believe that by intensively preparing 
the questionnaire and developing questions with the studied population in a 
face-to-face situation we increase the likelihood of the respondents 
acknowledging the questions and answering them as intended, thereby 
decreasing the risk of misclassification. 
The questionnaire was mailed to the participants. They had several weeks to 
complete the questionnaire in the privacy and security of their own home. We 
believe that this lowers the risk of potential interviewer-induced bias. The 
researchers were also independent from a clinical setting, which decreases the 
risk of “I-want-to-please-my-radiotherapist” bias. 
Step 4: Analytical adjustment 
Statistics are used to estimate effects of an association. Errors may occur due 
to confounders and other biases. In the ideal study the two categories of 
exposure (women receiving radiotherapy treatment or not) are supposed to 
resemble each other as much as possible (for example age and systemic 
treatment). In order to imitate the role model of studies – randomisation – and 
to make the comparison between the groups as perfect as possible we 
adjusted for possible risk factors as e.g. age and chemotherapy. Furthermore, 
to reduce the risk of significance due to a high number of questions in our 
questionnaire we pre-specified our hypothesis. We used relative risks as an 
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effect measure in many of the analyses since we believe that this is an 
understandable way of illustrating the clinical effect of a certain treatment for 
a clinician. 
 
5.2 General discussion  
To compare the occurrence of symptoms (late side-effects) 10 to 17 years 
after breast irradiation we used a cohort of women who were randomised to 
receive tangential breast irradiation or not after breast conserving surgery 
with axillary dissection due to breast cancer.  
We showed that the radiotherapy group did report breast pain and 
disturbances of skin sensation after radiotherapy significantly more often 
than those in the non-radiotherapy group. Even though the women who 
received radiotherapy in our study reported a higher occurrence of breast pain 
of any degree of severity, they did not report a statistically significant higher 
occurrence of the subcategory severe breast pain or a higher consumption of 
analgesics. When we asked about self-assessed quality of life there were no 
differences between the groups for problems in daily life related to pain or for 
quality of life. 
Pain in the breast area as a late adverse effect due to breast surgery with or 
without radiotherapy is previously known [105]. The background is not 
completely understood. Axillary dissection can injure the intercostobrachial 
nerve and cause pain. However, only 0.6% in the group with axillary 
dissection had breast pain compared to 8.8% in the group with both axillary 
dissection and radiotherapy of the breast, thus radiotherapy seems to be the 
main cause of this effect. Langer et al. [106] found that breast pain was 
equally common approximately 2.5 years after breast conserving surgery 
with sentinel node and radiotherapy compared to breast conserving surgery 
with axillary dissection and radiotherapy which also indicates that there is an 
alternative origin to pain besides the intercostobrachial nerve. Another known 
cause of chronic pain and severe mechanosensitivity is neuromas that can 
form whenever peripheral nerves are injured, as in scar tissues [107]. And in 
contrast to normal wound healing, we know that radiotherapy can prolong the 
fibrogenic process for a substantial time due to activated cytokines and 
growth factors [59, 108]. Possibly radiotherapy could affect the origination of 
neuromas and be a part in the complex pathophysiology. Regarding affected 
skin sensitivity we found that hypersensitivity is reported significantly more 
often in the radiotherapy group. Tasmuth et al [109] found a significantly 
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higher prevalence of paraesthesia in the breast-conserving group with 
radiotherapy compared to the mastectomy group without radiotherapy. 
Ververs et al found as well a more sensitive scar in women who underwent 
irradiation of the breast or chest wall compared to the women who did not 
receive radiotherapy [110]. Questions from women receiving radiotherapy 
about sensitivity to sun exposure are common issues in the daily work at the 
oncology department. We have not found any publications regarding this 
subject. Seven percent of the irradiated women report higher sensitivity to 
sun exposure if they compare to their contra lateral breast, and it affected the 
wellbeing in the radiotherapy group. The mechanisms behind these 
symptoms could be atrophy and fibrosis, that is well known late changes in 
the skin [111, 112] together with neuromas as described above. 
The occurrence of self reported oedema in breast or arm, erysipelas, heart 
symptoms, lung symptoms, rib fractures, and decreased shoulder mobility in 
women with breast cancer treated with breast-conserving surgery and 
postoperative radiotherapy was similar to that in women who had surgery 
only.  
We found no difference between the two groups regarding cardiovascular 
symptoms. To properly evaluate cardiotoxicity a greater number of patients 
and a longer follow-up time are probably needed. The cardiovascular effect 
of modern radiotherapy from the 1990s onward seems to have diminished 
with individual dose planning but that may also be explained by shorter 
follow-up [42]. Moreover, the risk of cardiovascular disease increases with 
radiotherapy to the internal mammary chains but these lymph nodes were not 
targeted in the women we have investigated [71].  
We proceeded in the research leading to the second article with a search for 
patient and treatment-related risk factors of developing long-lasting breast 
pain after breast cancer radiotherapy. Younger women who have undergone 
breast-conserving surgery with postoperative radiotherapy reported a higher 
occurrence of long-lasting breast pain compared with older women. In 
agreement with our study, previous studies have shown that age is an effect-
modifier and that younger women have a higher occurrence of pain after 
breast cancer treatment with or without radiotherapy than older women [80, 
105]. There is probably a combination of biology and psychology behind the 
age-related pain occurrence. Our findings are in contrast to the general 
Swedish female population where the general mean pain score increases with 
age, indicating that breast pain among young women is treatment related 
[113]. We also found that time since treatment decreases the frequency of 
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occurrence of pain. In the literature, some report a pain decrease over time 
[78, 114] whereas others report no relation to time elapsed [79, 115].  
The translation of the questions in the questionnaire before publication could 
initiate interpretation difficulties due to the complexity with both linguistic 
and cultural aspects. For example, in the Swedish questionnaire we used the 
phrase “ömhet i bröstet” and we used these words because this was a 
common phrase applied by the women during the interviews. The original 
question in the Swedish questionnaire was: “Har du känt ömhet i 
vänster/höger bröst det senaste halvåret?”. The answer category was: “Nej”, 
“Ja, vid enstaka tillfällen”, “Ja, åtminstone någon gång varje månad”, “Ja, 
åtminstone någon gång varje vecka”, “Ja, åtminstone tre gånger varje vecka”, 
“Ja, åtminstone någon gång varje dag”. When we made the translation we 
considered that the most appropriate English word in this context was pain. 
The occurrence of breast pain was lower or similar (5% and 13% in paper I 
and II) to others (15 to 73%) that asked about pain after breast cancer 
treatment in the literature [77, 78, 105, 114-116]. Whelan et al [114] 
investigated an English-speaking population and reported that 15% of the 
patients reported breast pain. In the START trials [117] pain in the breast 
area was reported by 20 to 23 % of the British women. Furthermore, in paper 
II we reported that women that had breast pain consumed analgesics every 
week significantly more often than the women without pain, 30.4% vs. 8.6% 
(RR 3.54; 95% CI 2.47-5.09), see page 32. Therefore we do not believe that 
we have made an overestimation of the symptom in the English version. 
We found a significantly higher occurrence of paraesthesia after axillary 
dissection and regional radiotherapy than after axillary dissection without 
regional radiotherapy in paper III. There were no significant differences in 
pain or in decreased strength between the different treatments. The women 
with neither axillary dissection nor regional radiotherapy reported the lowest 
occurrence of symptoms. We had no relation between the occurrence of 
paraesthesia and time after treatment in our cross-sectional study. Bajrovic et 
al. [118] presented an increase in the prevalence of neuropathy prevalence 
over time, 3.9% after 5 years and 24.5% after 10 years among women treated 
for breast cancer who received a total dose of 60 Gy with 3 Gy per fraction to 
the supraclavicular lymph nodes. In our study we used three-dimensional 
dose planning, a lower radiotherapy dose per fractionation, and a lower total 
dose, which could explain why we did not find any increase in prevalence of 
paraesthesia over time. This could also explain why we did not find any 
increased occurrence of pain or neurological motor deficits in the arm and 
hand after regional radiotherapy. The interval between treatment and 
symptoms probably depends on the total dose and the dose per fraction [119, 
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120]. A short follow-up time may underestimate the final occurrence of 
neuropathy and our follow-up of three to eight years could be too short to 
distinguish the occurrence of symptoms over time [118, 121]. However, 
Fathers et al. reported in 2002 that most patients developed their symptoms 
of neuropathy within three years, but some after eight years [122]. 
In addition to the paraesthesia we found a significantly higher occurrence of 
oedema after axillary dissection and regional radiotherapy than without 
regional radiotherapy. There is a strong relation between regional 
radiotherapy, oedema, and paraesthesia that makes it difficult to distinguish 
the causal factors of the paraesthesia. More than half of the women with 
paraesthesia after regional radiotherapy also had oedema. When adjusted for 
oedema the contribution from radiotherapy is no longer formally statistically 
significant. Therefore, we conclude that regional radiotherapy increases the 
risk of paraesthesia, however it can be mediated either directly by the plexus 
brachial nerve, indirectly via oedema, or in combination.  
Paraesthesia is a rather common symptom among the Swedish female 
population with a prevalence of approximately 17%, where e.g. carpal tunnel 
syndrome is represented by 5 % [123]. In our study we used the women that 
did not have axillary dissection as a reference for paraesthesia (8 %). To 
quantify the neuropathy in detail we would need to perform a clinical 
neurological and physiological examination including an electromyographic 
investigation (EMG) of the patients [124, 125]. However, since that approach 
was not part of this work the cause-effect must be interpreted with caution. 
We adjusted for having paraesthesia after regional radiotherapy with oedema. 
This resulted in the conclusion that the regional radiotherapy still numerically 
increased the risk of reporting paraesthesia but without statistical 
significance, RR 1.28 (95% CI 0.93-1.76). To better understand the relation 
between the regional radiotherapy (exposure) and paraesthesia (effect) we 
increased the precision of the exposure variable by doing a dose-volume 
response analysis with a delineation of the brachial nerve on the dose 
planning CT. Instead of only comparing regional radiotherapy or not we 
investigated; brachial nerve volume receiving 40 Gy or more (V40Gy), 
maximum dose in the brachial nerve, and prescribed regional dose. We found 
that among the women receiving regional radiotherapy with V40Gy >13.5 cm3 
25% reported paraesthesia, resulting in a significantly RR of 1.83 (95% CI 
1.13-2.95). The risk was still significant after adjustment for oedema (RR 
1.64; 95% CI 1.12-2.41). 
Our delineation of the brachial nerve is afflicted with several limitations. The 
main limitation is that the brachial nerve is not visible on the noncontrast CT; 
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the delineation is made indirectly guided by the borders of the surrounding 
tissues. However, as the brachial nerve passes right through the PTV we 
know that at least some volume receives the prescribed dose. Another 
limitation is the thickness of the CT scanning slices, 5 to 10 mm, which 
results in low precision of the estimated dose variable in the organ at risk. 
Furthermore, the anatomic normal variation of the brachial nerves is not 
possible to detect on the CT-scan [126]. Future studies in this field with 
regional radiotherapy due to breast cancer should delineate the brachial nerve 
as an organ-at-risk on magnetic resonance imaging (MRI), as has been 
proposed by Platteaux et al for radiotherapy due to head and neck cancer 
[127].  
It is well known that higher doses to the brachial nerve increase the risk of 
neuropathy; this has been shown by e.g. Powell [128], Olsen [125], and 
Johansson [129] when they compared different fractionation schedules. 
However, this is the first attempt to delineate the brachial nerve and search 
for a link between dose-volume and long-term symptoms after modern breast 
cancer radiotherapy. A small volume effect was also suggested by Emami et 
al [91] when they divided the brachial nerve into thirds, where irradiation of 
one third is a little more radioresistant than irradiation of all three thirds at the 
same time. Our results indicate that larger volumes of irradiation of >40 Gy 
to the brachial nerve seem to increase the occurrence of long-term 
paraesthesia. However, the results must be interpreted with caution. Further 
studies with higher precision in the delineation of the brachial nerve and with 
wider range of dose exposure are needed. 
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6 CONCLUSION 
 
The conclusions from our study regarding long-terms symptoms after 
external breast cancer radiotherapy are: 
• Postoperative radiotherapy to the breast after breast-
conserving surgery increases the risk of long-term breast 
pain. 
• Young women, below 50 years of age, have a higher risk of 
having breast pain after radiotherapy than older women. 
• The majority of the women have no or minor additional 
long-term symptoms after breast cancer radiotherapy 
compared to breast-conserving surgery only. 
• The addition of radiotherapy to the regional lymph nodes 
increases the risk of paraesthesia in the hand. 
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7 Future perspectives 
 
One way to reduce the side effects would be to reduce the irradiated volume 
of normal tissue [130]. However, this must be done without compromising 
the dose to the tumour cells. Since most local recurrences in the breast occur 
near the lumpectomy site [25], studies on partial breast irradiation is on-going 
as an alternative to the standard whole breast irradiation for selected groups, 
thereby reducing the volume of irradiated normal tissue (e.g. the breast, the 
lung, the heart). Methods of partial breast irradiation are e.g. brachytherapy 
(e.g. Mammosite – balloon intracavitary brachytherapy) [131, 132], IMRT 
(intensity-modulated radiation therapy) [133-135], and intraoperative 
radiotherapy [136, 137]. These radiotherapy techniques are often referred to 
as accelerated partial breast irradiation (APBI) since they also are 
hypofractionated. Results from these on-going randomised APBI-studies are 
expected relatively soon and may change the praxis for part of the breast 
cancer radiotherapy [138]. Breathing adapted radiotherapy (gating technique) 
[135, 139, 140] is another possible treatment modality and it aims to reduce 
the irradiated volume of normal tissue in the heart by increasing the space 
between the breast and the heart.  
The development of the image technologies; from x-ray to computed 
tomography (CT) and further to magnetic resonance imaging (MRI) and 
positron emission tomography (PET) [141] enhances the possibility for the 
physician to identify the target and thereby reduce the depicted extra margin 
volume in the normal tissue. 
When we better understand the relation between the tumour biology and 
patterns of recurrences we can treat patients with high risk and exclude 
treatment when the benefit of radiotherapy is expected to be very limited. 
This might be made possible by using gene expression profiling which has 
presented molecular subtypes based on similarities in gene expression: 
luminal A, luminal B, HER2 overexpressing (non luminal), and basal-like. 
Should all these breast cancer subtypes be treated equally or should we give 
hypofractionation, APBI, or even exclude the irradiation of women with a 
certain subtype? [46, 142, 143] The knowledge of “minor” radiotherapy side 
effects becomes more important when balancing the scale between pros and 
cons when we become able to predict subgroups with very limited gain from 
post-operative breast radiotherapy.  
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”Forewarned, forearmed; to be prepared is half the victory’’ said Miguel de 
Cervantes, author of the novel Don Quixote [144]. If we cannot avoid the 
side effects we need to present adequate information to the women. By 
informing the patients before the treatment and thereby make her a part of the 
planned treatment it will be easier to cope with possible side effects, i.e. 
enhance her preparedness.  
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